Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2576341 | 0.89 | ATM (0.57) | ATMALDH1A1CTSLCTSSCTSK | |
| SCHEMBL5981891 | 0.89 | ATM (0.57) | ATMALDH1A1CTSLCTSSCTSK | |
| SCHEMBL4184372 | 0.85 | ATM (0.58) | ATMCTSLCTSSCTSK | |
| SCHEMBL265847 | 0.85 | ATM (0.58) | ATMCTSLCTSSCTSK | |
| SCHEMBL5194569 | 0.85 | ATM (0.58) | ATMCTSLCTSSCTSK | |
| SCHEMBL9828589 | 0.85 | ATM (0.63) | ATMALDH1A1CTSLCTSSCTSK | |
| SCHEMBL9828584 | 0.85 | ATM (0.63) | ATMALDH1A1CTSLCTSSCTSK | |
| SCHEMBL14370505 | 0.84 | ATM (0.65) | ATMALDH1A1CTSLCTSSCTSK | |
| SCHEMBL29137641 | 0.84 | ATM (0.65) | ATMALDH1A1CTSLCTSSCTSK | |
| SCHEMBL10441764 | 0.83 | ATM (0.67) | ATMALDH1A1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060166895-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2006-07-27 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7026333-B1 | Retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060040974-A1 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-02-23 | — | — | US | disclosed |
| US-20050004230-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1447398-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030195227-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2003-10-16 | — | — | US | disclosed |
| EP-0641325-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| WO-2000002862-A1 | RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0957093-A2 | Retrovial protease inhibitors | MONSANTO COMPANY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5948790-A | VIRICIDES | MOSANTO COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5756534-A | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5648364-A | HETEROCYCLIC PEPTIDE COMPOUNDS AS ENZYME INHIBITORS | MONSANTO COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5643924-A | Retroviral protease inhibitors | MONSANTO COMPANY OF ST. LOUIS (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0641325-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023379-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | ATM 4588/4885ALDH1A1 2859/4885CTSL 24/4885 |
| US-20060040974-A1 | Retroviral protease inhibitors | PREP, TMPRSS15, DNPEP | ATM 4458/4885ALDH1A1 2626/4885CTSL 33/4885 |
| US-20030195227-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | ATM 4585/4885ALDH1A1 2763/4885CTSL 36/4885 |
| US-20050004230-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | ATM 4585/4885ALDH1A1 2763/4885CTSL 36/4885 |
| US-20060166895-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | ATM 4585/4885ALDH1A1 2763/4885CTSL 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.